Navigation Links
InVitria Launches Zap-CHO to Enhance CHO Cell Culture Performance
Date:10/1/2009

With Zap-CHO, customers get the animal free benefit of hydrolysates, the performance of FBS and the consistency of a defined media.

Fort Collins, CO (PRWEB) October 4, 2009 -- InVitria has launched a new and robust cell culture supplement for CHO (Chinese hamster ovaries) cell line enhancement called Zap-CHO. Zap-CHO is designed to deliver superior growth, maximum antibody productivity and faster cell line development and seed train expansion.

"Zap-CHO is a significant breakthrough in mammalian cell culture systems," said Dr. Steve Pettit, InVitria's Director of Cell Culture Development. "With the development of Zap-CHO, InVitria has created a performance enhancing CHO media supplement that is the first animal free supplement capable of replacing fetal bovine serum (FBS) without sacrificing performance and maintaining a well defined media. Since Zap-CHO is a defined and animal component-free product, it is well suited for commercial, chemically-defined and serum- and animal-free cell culture media formulations," said Dr. Pettit.

Zap-CHO is a next generation media supplement that delivers consistent cell culture performance. Previously, only FBS could deliver equivalent performance, but safety concerns of a fetal bovine component in cell culture media forced many customers away from this component. In the last decade, customers have eliminated FBS in cell culture media only to lose cell culture performance. To regain the lost performance, many began adding hydrolysates to the media. However, hydrolysates introduced significant variability, leading to failed experiments and production failures. Zap-CHO addresses these concerns and provides significant benefits in CHO cell culture, including:

 
  • Faster cell line development and seed train expansion
  • Animal component-free
  • Consistency of a defined media component
  • Biomanufacturing optimization and improved production economics
  • Better and more predictable performance in cell culture research and development

"Our product development team created Zap-CHO to exceed the needs of our customers working in CHO cell culture," said Scott Deeter, InVitria's President and CEO. "Our customers have realized exceptional performance results using Zap-CHO. InVitria's products, like Zap-CHO, are creating a new era for the cell culture manufacturing industry."

About InVitria
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media components and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria's products or to order, please contact InVitria at info@invitria.com or call 1-800-916-8311. InVitria's products can also be purchased online Click Here.

###

Read the full story at http://www.prweb.com/releases/InVitria-ZapCHO/CHO-cell-culture-media/prweb2975014.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. InVitria's Better Ingredients for Better Media to be Showcased at BPI '09
2. InVitria Presents Zap-CHO Performance Results at PEACe Conference
3. InVitria Successfully Completes Beta Testing and Announces Commercial Launch of Optiferrin for Mammalian Cell Culture
4. InVitria Cell Culture Product Line to Headline PEACe
5. InVitria Sponsors ESACT 2009 in Dublin, Ireland
6. InVitria to Present at BIO 2009 International Convention in Atlanta
7. InVitria Reveals Technology to Optimize Hybridoma Production Performance
8. InVitria Headlines Sponsorship of WilBio's Waterside Conference
9. InVitria Announces Launch of Recombinant Albumin for Diagnostics
10. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
11. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... Those who have experienced traumatic events may suffer from ... avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid this ... coping following a traumatic event. , Trauma sufferers tend to feel a range of ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Tenn. , June 24, 2016  Arkis ... providing less invasive and more durable cerebrospinal fluid ... in funding.  The Series-A funding is led by ... Lighthouse Fund, and other private investors.  Arkis, new ... neurosurgical instrumentation and the market release of its ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: